



LUND UNIVERSITY

Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios

Hoogendoorn, Martine; Feenstra, Talitha L; Asukai, Yumi; Borg, Sixten; Hansen, Ryan N; Jansson, Sven-Arne; Samyshkin, Yevgeniy; Wacker, Margarethe; Briggs, Andrew H; Lloyd, Adam; Sullivan, Sean D; Rutten-van Mülken, Maureen P M H

Published in:
Value in Health

DOI:
[10.1016/j.jval.2014.03.1721](https://doi.org/10.1016/j.jval.2014.03.1721)

2014

[Link to publication](#)

Citation for published version (APA):

Hoogendoorn, M., Feenstra, T. L., Asukai, Y., Borg, S., Hansen, R. N., Jansson, S.-A., Samyshkin, Y., Wacker, M., Briggs, A. H., Lloyd, A., Sullivan, S. D., & Rutten-van Mülken, M. P. M. H. (2014). Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. *Value in Health*, 17(5), 525-536. <https://doi.org/10.1016/j.jval.2014.03.1721>

Total number of authors:
12

General rights

Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Cost-effectiveness models for chronic obstructive pulmonary disease (COPD): cross-model comparison of hypothetical treatment scenarios

Running title: comparing COPD cost-effectiveness models

Martine Hoogendoorn ¹, Ph.D.

Talitha L. Feenstra ^{2,3}, Ph.D.

Yumi Asukai ⁴, M.Sc.

Sixten Borg ^{5,6}, M.Sc.

Ryan N. Hansen ⁷, Pharm.D., Ph.D.

Sven-Arne Jansson ⁸, Ph.D.

Yevgeniy Samyshkin ⁴, M.Sc.

Margarethe Wacker ⁹, M.Sc.

Andrew H. Briggs ¹⁰, DPhil.

Adam Lloyd ⁴, MPhil

Sean D. Sullivan ⁷, Ph.D.

Maureen P.M.H. Rutten-van Mölken ¹, Ph.D.

¹ Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands

² Department for Prevention and Health Services Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

³ Department of Epidemiology, University Medical Centre Groningen, Groningen, The Netherlands

⁴ IMS Health, Economics and Outcomes Research, Real-World Evidence Solutions, London, UK

⁵ The Swedish Institute for Health Economics, Lund, Sweden

⁶ Health Economics Unit, Department of Clinical Sciences Malmö, Lund University, Sweden

⁷ Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA

⁸ The OLIN studies, Luleå, Sweden

⁹ Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Member of the German Center for Lung Research, Comprehensive Pneumology Center Munich, Neuherberg, Germany

¹⁰ Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Correspondence and request for reprints:

M. Hoogendoorn

Erasmus University, Institute for Medical Technology Assessment

P.O. Box 1738

3000 DR Rotterdam

The Netherlands

Phone: *31 10 4088871

Fax: *31 10 4089081

Email: hoogendoorn@bmg.eur.nl

Financial support

This study was financially supported by Boehringer Ingelheim International, Boehringer Ingelheim The Netherlands, GlaxoSmithKline, Novartis and Takeda Pharmaceuticals

Key words:

COPD, model, progression, exacerbations, probabilistic

Abstract

Objectives: To compare different COPD cost-effectiveness models with respect to structure and input parameters and to cross validate the models by running the same hypothetical treatment scenarios.

Methods: COPD modeling groups simulated four hypothetical interventions with their model and compared the results with a reference scenario of no intervention. The four interventions modeled assumed: 1) 20% reduction in decline in lung function, 2) 25% reduction in exacerbation frequency, 3) 10% reduction in all-cause mortality and 4) all these effects combined. The interventions were simulated for a five-year and lifetime horizon with standardization, if possible, for sex, age, COPD severity, smoking status, exacerbation frequencies, mortality due to other causes, utilities, costs and discount rates. Furthermore, uncertainty around the outcomes of intervention four was compared.

Results: Seven out of nine contacted COPD modeling groups agreed to participate. The 5-year cost-effectiveness ratios (ICERs) for the most comprehensive intervention, intervention four, was €17,000/QALY for two models, €25,000-€28,000/QALY for three models and €47,000/QALY for the remaining two models. Differences in the ICERs could mainly be explained by differences in input values for disease progression, exacerbation-related mortality and all-cause mortality with high input values resulting in low ICERs and vice versa. Lifetime results were mainly influenced by the input values for mortality. The probability of intervention four to be cost-effective at a willingness-to-pay of €50,000/QALY was 90-100% for five models and about 70% and 50% for the other two models, respectively.

Conclusions: Mortality was the most important factor determining the differences in cost-effectiveness outcomes between models.

Introduction

Chronic obstructive pulmonary disease (COPD) is a chronic condition characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lungs to noxious particles or gases [1]. Most important respiratory symptoms are cough, sputum production and dyspnea. Patients regularly experience exacerbations, which are periods of increased symptoms, often leading to increased use of healthcare, hospital admission or even death [2-6]. Prevalence estimates of COPD are as high as 11.4 to 26.1% for the population above 40 years of age [7]. COPD is associated with a significant impairment of quality of life and substantial health care use especially in the more severe stages [8]. The Global Burden of Disease study 2010 showed that COPD is the third leading cause of death and the ninth cause of disability-adjusted life years worldwide [9,10]. In most Western countries age-specific prevalence rates are stable or decreasing in men but increasing in women. Due to ageing of the population the absolute number of patients is still expected to increase substantially in the coming decade. COPD is projected to be the fifth leading cause of disability worldwide in 2030 [11]. This puts increasing pressure on health care expenditures, which are already rising with 4% each year in European countries [12]. It also puts pressure on the limited capacity of pulmonary hospital wards. Against this background, information on the cost-effectiveness of the increasing number of treatment options for COPD becomes more and more important to guide reimbursement decision making. Such information can be obtained from clinical trials. But in a slowly progressing disease such as COPD, these trial data are often complemented with cost-effectiveness models that facilitate extrapolation of trial data to a longer time horizon and comparisons between treatments that have not been compared head-to-head in a clinical trial.

In the last decade several cost-effectiveness models for COPD were published. Inspired by the Mount Hood Challenge Meetings for diabetes modelers the authors MH, TF and MR took the initiative to organize a round-the-table meeting in 2011 for COPD modeling groups to present their model, discuss data availability and share their experience. A second meeting was organized in 2012 focusing on cross validation. The different modeling groups were asked to run the same pre-specified hypothetical interventions with their model after standardizing (part of) the input parameters. This way the impact of differences in input variables and/or assumptions between the models was investigated.

Such cross validation is one of the five main types of model validation as described by the ISPOR-SMDM Modeling Good Research Practices Task Force [13].

The aim of the current paper was to compare different COPD models with respect to structure, input parameters and implementation and to cross validate the models by running hypothetical treatment scenarios. This contributes to a better understanding of the impact of different modeling choices on the outcomes.

Methods

Early in 2012 a steering committee of six people experienced in COPD modeling was formed (MR, TF, AB, SB, AL and SS). The main task of this committee was to prepare the second modeling meeting (i.e. date, location), discuss the content of the treatment scenarios (i.e. standardization of input parameters, type of interventions) and discuss the current paper. In May 2012 several COPD modeling groups were contacted to explore their interest in participating in the second COPD modeling meeting and in running the treatment scenarios with their models. Modeling groups were requested to complete two parts. First, the groups were asked to simulate four hypothetical interventions and compare the results with the situation in which no intervention would have been provided. The second part focused on the types of uncertainty included in the model and the uncertainty around the outcomes of the fourth intervention. Data were reported in a structured Microsoft Excel spreadsheet and returned to the organizers of the meeting two weeks before the meeting took place. A structured overview of the results of the different models was provided to all participants during the meeting as input for the discussion. After the meeting, modeling groups were contacted once or twice to provide clarifications or to perform additional or re-analyses.

Overview of participating models

In total nine comprehensive COPD models were identified based on a search in PubMed and through personal communication with modelers in the field [14-22]. In total, seven modeling groups agreed to participate [14-20]. The model of Spencer et al. [22] did not participate, because the company who funded the work was in the middle of developing a new model. Furthermore the Burden of Obstructive Lung Disease (BOLD) model was not represented [21], because no modelers of this

group could be present at the meeting. All of the seven participating models were state-transition models and assumed the Markov property, but varied in the number of health states and the duration of a cycle. One patient-level model was included [15]. All models used the Global Initiative for Chronic Obstructive Lung Disease (GOLD) lung function classification published in 2003 to define COPD severity stages [23]. All of them modeled the incidence of COPD exacerbations, but in different ways. For all but one model [18], the maximum time horizon was lifetime. A short description of participating models is given below. Details and data sources for two important parameters, disease progression and mortality, are described in Table 1 and 2, respectively.

Indacaterol COPD model (by Price represented by Asukai) [14]

The indacaterol COPD model published in 2011 was developed to estimate the cost-effectiveness of the bronchodilating agent indacaterol versus other long-acting bronchodilators. The model, funded by Novartis, could be characterized as a state-transition cohort model with a cycle length of three months and was constructed in Microsoft Excel. The model had 13 health states, four COPD severity states each further extended by two health states for a non-severe and severe exacerbation, and death. The COPD population at the start was based on two large trials for indacaterol and specified by COPD severity. Disease progression in terms of lung function decline was derived from the UPLIFT trial (Table 1). Mortality was subdivided into COPD-related mortality and all-cause mortality. Mortality due to exacerbations was not modeled separately (Table 2). The model was validated by comparing life expectancy with several epidemiology sources for COPD which showed that mortality probabilities in the model were similar to external data.

Swedish Generic model of disease history and economic impact of COPD (represented by Borg) [15]

The Swedish Generic model of disease history and economic impact of COPD was published in 2004 and financed by AstraZeneca. The main purpose of the model, implemented in Splus 2000 Professional, was to evaluate the cost-effectiveness of new interventions for COPD. The model has seven health states, one for mild COPD, two states for moderate, two states for severe, one state for very severe COPD and death. The model has two health states each for moderate and severe COPD because backward transition is allowed up to one milder health state, but not further. Exacerbation status was modeled as separate states within each severity state and subdivided into exacerbation-

free, mild, moderate and severe exacerbations. The two-dimensional Markov chain model simulated individual patients using two different cycle lengths: one year for disease progression and mortality and one week for exacerbation status. The model was populated with data on COPD patients detected during screening of the general population in Northern Sweden, the OLIN studies [24]. Transition probabilities between COPD severity states and mortality were obtained from 10-year follow-up data from the OLIN studies and modeled to depend on age, COPD severity and exacerbations (Table 1 and 2). The model used primary data validated against published sources with satisfactory results. For the present work, the model was restored from the archive and set up to execute. However, the optimized version of the computation engine could not be compiled in the current computer environment and therefore only a limited number of patients could be simulated, resulting in poor precision in the estimates.

US Dynamic Cohort COPD model (represented by Hansen) [16]

The Dynamic Cohort COPD model developed in the US to evaluate the cost-effectiveness of a broad range of COPD interventions was not yet published at the time of the modeling meeting but has been presented during the ISPOR Annual International Meeting of 2012. The model implemented in Microsoft Excel had 16 states: four COPD severity stages further subdivided into three separate states: stable disease, outpatient or inpatient managed exacerbations, three end-stage treatments (i.e. lung rehabilitation, lung volume reduction surgery and lung transplantation) and death. The starting population of the model represents the US COPD population. Disease progression in terms of transition probabilities to the next severity stage was adapted from Atsou et. al.[25] which uses the BOLD cohort [20] and Hoogendoorn et. al. [27] and is specified by age and smoking status (Table 1). Health related quality of life was mapped from the St. George Respiratory Questionnaire [26]. Mortality was divided into all-cause mortality and mortality associated with outpatient and inpatient managed exacerbations (Table 2). The model was validated by performing a variety of internal checks and comparison to the Lung Health Study.

Dutch Dynamic population COPD progression model (represented by Hoogendoorn) [17,27,28]

The latest version of the Dutch dynamic population COPD progression model was published in 2011 and was used to estimate the cost-effectiveness of a wide range of interventions for COPD. The

model sponsored by the Lung Foundation Netherlands is representative for the Dutch COPD population. It is a state-transition model with a cycle length of one year and has six main health states: no COPD, four COPD severity stages, and death. Each stage is further specified by sex, one-year age classes and smoking status. Moderate and severe exacerbations are modeled as events within each severity state. The model is dynamic because it takes into account changes in the general population due to birth, changes in smoking behavior and mortality. Changes in the COPD population over time are the result of new incidence, changes in smoking behavior, disease progression and mortality. Disease progression was modeled as annual decline in lung function specified by sex, age, smoking status and disease severity based on a re-analysis of the original 5-year Lung Health Study data (Table 1) [27]. Total mortality consisted of mortality related to severe exacerbations, other COPD-attributable mortality and mortality due to other causes (Table 2). The model was implemented in Mathematica 7 and was validated by performing several internal checks and by comparing the results with other models [29].

Tiotropium COPD model (represented by Rutten-van Mölken) [18]

The 5-year version of the tiotropium COPD model was implemented in Excel and published in 2007. The model was developed to estimate the cost-effectiveness of tiotropium (Boehringer Ingelheim) versus other bronchodilators. The state-transition cohort model with a cycle length of one month has four health states: moderate, severe and very severe COPD and death. Exacerbations were modeled as events within severity states and specified as non-severe or severe. The COPD population at the start reflected the patient population included in the tiotropium trials. These were mainly severe and very severe COPD patients. The distribution of the lung function of the moderate COPD patients in this population was located at the severe end of the lung function range for moderate COPD. Disease progression in the first year was based on data from six tiotropium trials. Because these trials showed an increase in lung function in the first year in part of the patients, backward transition to a less severe COPD stage is possible in the first year. For the following years annual decline in lung function was obtained from the Lung Health Study (Table 1). Mortality was modeled as all-cause mortality specified by COPD severity. Exacerbation-related mortality was not modeled separately (Table 2). One-year model results were validated against 1-year trial data resulting in comparable numbers of exacerbations [30].

Roflumilast COPD model (represented by Samyshkin) [19,31,32]

The recently published Roflumilast COPD model (2012/2013) was developed to estimate the cost-effectiveness of roflumilast versus several comparators. The model, which development was financed by Takeda, was a state-transition cohort-based model implemented in TreeAge Pro Suite 2009 with a Microsoft Excel front-end . The structure of the original model included three health states: severe COPD, very severe COPD and death; the cycle length in the model was one month. For the purpose of this exercise the model was extended with the state “moderate COPD”. Exacerbations are modeled as events that can occur within each of the COPD severity states, and are specified as moderate or severe. The population in the severe and very severe states of the model was based on the patient population of the LABA alone group of two large roflumilast trials. Disease progression, i.e. annual decline in lung function was derived from the Lung Health Study (Table 1). Mortality was modeled as a combination of background mortality estimated from the general population from life tables adjusted to the standardized mortality ratio (SMR) for COPD and mortality due to severe exacerbations (Table 2).

German comprehensive care COPD model (by Menn, represented by Wacker) [20]

The German comprehensive care COPD model published in 2012 was developed with financial support of the Competence Network Asthma/COPD (Federal Ministry of Education and Research). The model was implemented in TreeAge Pro 2007. Main purpose of the cohort model was to evaluate the cost-effectiveness of COPD interventions in the German context. The model has seven states: four COPD severity states, one state after lung volume reduction surgery, one state after lung transplantation and death. Cycle length is three months. Mild, moderate and severe exacerbations are modeled as events within disease states. Starting point of the simulation is a 45-year old patient with mild COPD. Disease progression for mild and moderate COPD was based on the Lung Health Study specified by smoking status. The ISOLDE and TORCH trial were used to obtain estimates of the annual decline in severe COPD in smokers (Table 1). All-cause mortality was divided into mortality in stable disease, mortality associated with severe exacerbations and for very severe COPD mortality associated with surgery and transplantation (Table 2). Model validation was performed by comparing

the results with observed data: the severity distribution among smokers and quitters in the Lung Health Study and the total exacerbation probabilities of the TRISTAN trial.

Standardization of the reference scenario

To increase comparability among the different models, groups were requested to run their model for a male patient or cohort of male patients with moderate COPD, ex-smoking and 65 years of age. Furthermore, groups were asked to standardize exacerbation frequencies, mortality due to other causes, utilities and costs (Table 3). The probability distribution for the parameters used in the probabilistic sensitivity analysis (PSA) was not standardized. All analyses were performed using a 3% discount rate for both effects and costs. The probabilities for end-stage treatment options and mild exacerbations were set to zero if included in the model. A model simulation with the standardized parameters was considered the reference scenario.

Hypothetical interventions

Four different interventions were defined reflecting the broad range of possible interventions available for COPD. Effect sizes and costs were hypothetical and not based on any clinical trial. The first intervention assumed a 20% reduction in annual decline in lung function or, if this was not possible, a 20% reduction in transition probabilities between COPD severity stages. Annual costs for this intervention were assumed to be €200 per patient. The second intervention assumed a 25% reduction in the total exacerbation frequency with annual costs of €400 per patient. When applying this intervention groups were asked to keep the ratio between exacerbations with a different severity constant. For intervention three, groups modeled a 10% reduction in total mortality. Annual costs were €300 per patient. The fourth intervention consisted of the combination of all three effects of the first three interventions, 20% reduction in annual decline in lung function, 25% reduction in exacerbation frequency and 10% reduction in mortality, with annual costs of €700 per patient.

Outcomes

Each modeling group ran the hypothetical interventions for two different time horizons: five year and lifetime. For both time horizons groups reported the following outcomes: mean number of exacerbations per patient, mean number of life years, quality-adjusted life years (QALYs) gained and

incremental costs per patient and the incremental cost-effectiveness ratio (ICER) compared to the reference scenario. In addition, the severity distribution over the COPD severity stages after five years and the percentage of patients that died were provided for the five year horizon, while for the lifetime analysis the time spent in each severity stage was reported.

Uncertainty

For the second part of the exercise, groups provided details about uncertainty around the outcomes of intervention four, a 20% (SE 4) reduction in annual decline in lung function, 25% (SE 5) reduction in exacerbation frequency and 10% (SE 2) reduction in mortality, with annual costs of €700 per patient using a five-year time horizon. Ninety-five percent confidence intervals were given around the mean number of QALYs and mean costs for the intervention and the usual care scenario as well as the difference in QALYs and costs. Furthermore, each modeling group displayed the uncertainty around the outcomes in an acceptability curve with willingness-to-pay values between 0 and €100,000 per QALY.

Results and explanations

Comparison of reference scenario

Five-year model outcomes for the reference scenario after standardization of requested input parameters are shown in figure 1. In five out of seven models the percentage of patients still in moderate COPD after five years was around 60-70%. In the model of Borg et al. 10% of the patients regressed to mild COPD and about 55% remained in moderate COPD, while in the model of Rutten 20% of the patients remained in moderate COPD and 32% progressed to severe COPD. Further comparison of the seven models showed that the percentage of patients that has died after five years ranged from 14% to 31%. The mean number of QALYs varied between 2.7 and 3.7. The mean 5-year costs per patient for the models of Asukai, Borg and Menn/Wacker were around €4,000 (range €3,743 to €4001). For the other four models the mean costs varied between €5,097 for the model of Samyshkin and €5,806 for the model of Hansen. Differences were larger but comparable in ranking for a lifetime time horizon (data not shown). Despite the standardization the outcomes for the

reference scenario still showed substantial variation between the models, especially regarding survival.

Intervention one: disease progression

For the models of Asukai, Hoogendoorn and Samyshkin this intervention was implemented as a 20% reduction in annual decline in lung function. The other models applied a 20% reduction in transition probabilities to worse states. Based on the results the impact of altering decline or altering probabilities seemed minimal. Using a five-year time horizon the differences in cost-effectiveness ratios for intervention one (Table 4) could mainly be explained by the differences in transition probabilities between the models, except for the models of Borg and Hansen. In general models with high transition probabilities to worse severity stages, such as the model of Rutten (see Table 1) benefit most from a 20% reduction in transition probabilities and thus reported the lowest ICERs. In accordance with this, models with low transition probabilities, such as the models of Menn/Wacker and Hoogendoorn, found a high ICER. The model of Hansen et al found a high ICER in comparison with other models given the relatively high transition probabilities (Table 1). The model of Borg reported a very high cost-effectiveness ratio due to a (nearly) zero difference in QALYs, which could be explained by poor precision due to small number of simulated patients, or that some patients spend time in mild COPD where there is relatively little disease progression risk to be reduced (thus little benefit of the intervention) while the cost of the intervention is still accrued.

Using a lifetime horizon the ICER is influenced by a combination of the transition probabilities to the next severity stage as well as the probability of death. The model of Menn/Wacker with a low transition probability to more severe stages and a high probability to die found the highest ICER (Table 5), because the absolute gain in effect is relatively low and the time to gain effect is relatively short, on average 7.2 life years. The model of Asukai with the lowest annual mortality probability reported the most favorable ICER, because the time to gain effect was the longest, on average 14.8 life years.

Intervention two: exacerbations

Differences in outcomes for intervention two, a 25% reduction in exacerbation frequency, could mainly be explained by differences in exacerbation-related mortality. For the five-year time horizon the model

of Menn/Wacker and Hoogendoorn both resulted in low costs per QALY (Table 4), because of the relatively high mortality associated with exacerbations in comparison with other models (see Table 2). The models of Asukai and Rutten reported a high ratio because exacerbations did not have an impact on mortality, so the gain in the QALYs was only the result of a gain in quality of life and not a gain in life years. The model of Rutten et al. reported a lower ICER than the model of Asukai et al, because in the first model patients progress faster to a more severe health state associated with higher exacerbation rates and therefore higher absolute gains in QALYs compared to the situation in which patients remain in moderate COPD for a longer time period. The model of Hansen reported the highest ICER which was unexpected given that this model included an increased mortality risk associated with both moderate and severe exacerbations. When models were ranked according to the ICERs for the lifetime time horizon, the ranking was comparable to the five-year time horizon (Table 5).

Intervention three: all-cause mortality

Results of intervention three, a 10% reduction in total mortality, could be explained by the input values for mortality used in the models (Table 2). The five-year results showed that in the models of Menn/Wacker and Rutten for which mortality probabilities in the first year were the highest, around 7%, a 10% reduction in mortality probability had the highest impact and therefore the ICERs were the lowest (Table 4). For the models of Asukai and Samyshkin with the lowest mortality probabilities, around 3%, the ICERs were the highest. Based on the ranking of the mortality probabilities in the first year the ICER for the Borg model was higher than expected when compared to the other models, while the ICER for the model of Hansen was lower than expected. Results of the ICERs for the lifetime time horizon were comparable in ranking to the five-year results (Table 5), except for the model of Asukai that resulted in the lowest ICER although this model had the lowest mortality probability in the first year.

Intervention four: combination of three effects

In all models the three effects of intervention four were not calibrated. This means that it was not taken into account that for example a reduction in exacerbation frequency already leads to a reduction in mortality in most models. For the current exercise effects of intervention four were implemented

independently. As a result, the gain in QALYs for intervention four was fairly comparable to the sum of QALYs gained in the first three interventions in six out of seven models. Differences in cost-effectiveness results between the models for intervention four are more difficult to explain, because these are the result of simultaneous changes in three different parameters. However, mortality seems to be the driving factor. The model of Menn/Wacker using the highest values for total mortality and exacerbation-related mortality, but the slowest disease progression reported the most favorable ICER. The model of Asukai which used moderate values for disease progression, the lowest value for total mortality and no additional mortality for exacerbations found one of the highest ICERs (Table 4).

Uncertainty

A list of parameters for which uncertainty is included in the models can be found in Appendix I. Figure 2 shows the 95% confidence intervals around the difference in QALYs and costs for intervention four using a five year time horizon. Figure 3 shows the acceptability curve for intervention four. Six models showed curves that had roughly the same shape, with a relatively steep increase of the probability of the intervention being cost-effective. The thresholds at which a 90% cost-effectiveness probability was reached varied from €30,000 to €60,000 for these models. The acceptability curve for the model of Hansen increased very gradually and reached a 90% confidence level at a €85,000 threshold.

General discussion

This cross model validation study aimed to compare different COPD models by explaining the results of the evaluation of four hypothetical interventions that affected lung function decline, COPD-exacerbations, all-cause mortality or all three of these based on the differences in model structure and input parameters. Differences in the results of the deterministic analyses could, in general, be explained by structural uncertainty and by the rank-order of input values used for disease progression, exacerbation-related mortality and total mortality in the models. Mortality was the most important factor determining the QALY outcomes, especially for a lifetime time horizon. For example, for the intervention that assumed a 20% reduction in disease progression, the differences in transition probabilities to more severe disease states were of less importance for the lifetime results than the values used as input for total mortality. A substantial part of the differences in the results of the

deterministic analyses was the result of structural uncertainty in each model. Structural uncertainty is characterized by assumptions about the structure of the model, such as the as the number of COPD severity states, the possibility of backward transition to less severe states and the inclusion of exacerbation-related mortality [33]. Mortality was one of the parameters with the most variation in the way it was modeled. Most models specified mortality into two types: non-COPD related mortality and COPD-related mortality. However, the concept of non-COPD related mortality does not mean the same in all models. Some models define this as the all-cause mortality rate in the general population, while other models define this as all non-COPD related mortality among COPD patients, including the increased risk to die of other –mostly smoking-related- diseases (Table 2). In some models COPD-related mortality equals exacerbation-related mortality, while in other models exacerbation-related mortality is part of COPD-related mortality and includes also COPD-attributable mortality that is not related to exacerbations (Table 2). These differences in definition hinder comparison between models with respect to mortality. These differences also cause the same intervention (e.g. an intervention that reduces exacerbation rate with 25%) to have different mortality effect sizes, depending on the model. Therefore, it is of utmost importance to aim for consensus on how mortality is best modeled and what data to use for this. Modeling mortality from COPD exacerbations separately obviously leads to more favorable cost-effectiveness ratios of interventions that reduce exacerbation rate than not doing so.

When comparing the results of the PSA for intervention four, differences do not only result from differences in model structure and input values, but also from parameter uncertainty. Parameter uncertainty results from the fact that a parameter value is estimated from a sample and the “true” value is unknown. This uncertainty is represented by a probability distribution for each parameter [33]. Although the uncertainty around utilities, costs, COPD exacerbation probabilities and mortality from other causes than COPD was standardized by providing a standard error the differences in uncertainty around the estimated difference in QALYs and costs for intervention four were still substantial. This was probably caused by the uncertainty around other non-standardized parameters, such as disease progression and COPD-related mortality, and/or differences in the type of probability distributions around parameters used in the PSA. For example, there is a more than two-fold difference between the models in the point estimate of the QALY gain due to intervention four (from 0.054 to 0.12) and a 14-fold difference in the width of the 95% confidence interval around the QALY

gain (from 0.011 to 0.151) (Figure 2). The probability that intervention four was cost-effective at a threshold value of €50,000 ranged from 45% to almost 100%.

Differences with regard to structure and input parameters can often be explained by the model's purpose. Some of the models are more universal in the sense that they can be used for a range of problems, while other models were built for a specific application, e.g. the extrapolation of the results of a trial. The results of the indacaterol model for example were mainly influenced by mortality being independent from exacerbations. The primary endpoint in the indacaterol trials used as input for the model was the change in lung function in the first 12 weeks. Therefore less emphasis was put on modeling the impact of exacerbations on mortality. The results for the tiotropium model could mainly be explained by the high disease progression in this model. In this model disease progression for the first year was based on data from six trials. These trials mainly included patients with severe and very severe COPD. The few patients with moderate COPD (about 20% of all patients in the original trials) had a FEV₁% predicted close to the cut-off point for severe COPD, resulting in a high probability to move from moderate to severe COPD. In the original, non-standardized version of the model this fast progression is compensated by a relatively high probability to move back from severe to moderate COPD in the first year due to an improvement in lung function in part of the patients after start of the medication. However, because the scenarios described a moderate patient instead of a patient population with mixed severity, the percentage of patients moving back from severe to moderate is very small. Moreover, the definition of the health states in this model was based on pre-bronchodilator FEV₁, which increases the severity of the populations and the probability to move into a more severe health state. In retrospect, this model seems less suitable to use for analyses for a cohort of moderate COPD patients.

Cross validation of models may increase confidence in the results if similar results are found by different models [13]. However, one of the limitations of this approach is that finding similar results does not mean that results are valid. Agreement may be the result of using the same structural assumptions and data sources for input. The Lung Health Study for example was used as single or combined data source by five of the seven models to estimate disease progression. Another limitation of our current cross validation exercises is that, by running hypothetical interventions with the models

only the differences between the models can be explained, but not which models perform best. Although effectiveness of the interventions lies within the range of effect sizes observed in COPD interventions, using hypothetical interventions may also have reduced the clinical relevance. Real life data are needed to further validate the models. During the Mount Hood Challenge Meetings for diabetes modeling this was done by performing simulations of outcomes for patients published in clinical trials [34-36]. Validation against real life data may be topic of future COPD modeling meetings. The availability of well-performed COPD trials with a follow-up of several years is however limited [37,38].

To make the results of the treatment scenarios more comparable part of the input parameters were standardized. Models were asked to run the scenarios for a male, ex-smoking patient aged 65 years with moderate COPD. All models were able to standardize for disease severity, exacerbation frequency, utilities and costs. However, for the model of Hansen standardization of exacerbation-related parameters was done differently than in the other models, because the total number of exacerbations was not an outcome in this model, only exacerbation days. Therefore the standardized input values for exacerbation utility decrement and costs were divided by the mean number of days of an exacerbation and applied as the mean utility decrement or costs per exacerbation day.

Standardization with respect to other parameters was occasionally difficult. The model of Rutten was not standardized for sex and age and the model of Borg was not standardized for sex, because these patient characteristics were not included as model parameters. Not standardizing for age could have had a large impact on especially the results of the lifetime analysis. However, the maximum time horizon for the model of Rutten was five years. Only three models [16,17,20] were able to standardize for smoking status, because smoking status was not considered in the other models. The model of Hoogendoorn was the only model taking into account restart rates for smoking. The impact of these restart rates on the results for the current analyses was minimal; after five years more than 95% of the cohort was still ex-smoker. Finally, the model of Borg was not able to standardize background mortality, while in the model of Rutten only all-cause mortality could be standardized, because this is the only type of mortality included in this model. However the type of mortality that is standardized seemed of minor importance because total mortality rates are different between models anyway. The choice of parameters needing standardization was made by the steering committee and comprised

finding a balance between getting comparable results versus maintaining the specific character of the models.

The severity distribution for COPD used in all models was based on the degree of airflow limitation. In 2011 the GOLD committee proposed a new grading of COPD severity based on airflow obstruction, exacerbations and symptoms, to better capture the complexity of COPD. Currently the prognostic value of this new classification is being investigated [39-41]. Changes in the structure of the models to this new classification need to be considered, if treatment effects and cost-effectiveness results are found to be different between the different severity classes. However, this would also have an influence on the type of model. All models included in the current paper were Markov models. Using more parameters than lung function alone to define COPD severity would increase the number of health states exponentially and substantially increase the complexity of the model structure as well the input data required. Current COPD models under development or recently published models are therefore exploring microsimulation modeling or structured equation modeling [42,43]. The advantage of such approaches is that heterogeneity of the patient population can be better taken into account in the model, which is becoming more and more important because treatment for COPD is increasingly personalized.

In conclusion, this paper describes the comparison of seven cost-effectiveness models for COPD by means of the results of four hypothetical interventions and tries to explain the differences in outcomes based on differences in structure and input data for mortality and disease progression. Mortality was shown to be the most important factor determining the differences in cost-effectiveness outcomes. Validation against real life data is needed to further validate the models.

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. <http://www.goldcopd.com> (accessed June 2013), 2013.
2. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. *Am J Med* 1995; 98: 272-7.
3. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. *Arch Intern Med* 2003; 163: 1180-6.
4. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). *Respir Med* 2002; 96: 700-8.
5. Oostenbrink JB, Rutten-van Molken MP. Resource use and risk factors in high-cost exacerbations of COPD. *Respir Med* 2004; 98: 883-91.
6. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. *Int J Clin Pract* 2007; 61: 1112-20.
7. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007; 370: 741-750.
8. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B. Costs of COPD in Sweden according to disease severity. *Chest* 2002; 122: 1994-2002.
9. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2095-2128.

10. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2197-2223.
11. World Health Organization. the Global Burden of Disease: 2004 Update. World Health Organization (WHO), Geneva, Switzerland, 2008.
12. OECD. Health Expenditure in Relation to GDP, in Health at a Glance: Europe 2012. OECD Publishing, <http://dx.doi.org/10.1787/9789264183896-53-en>, 2012.
13. Eddy D, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model Transparency and Validation: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group - Part 4. *Value Health* 2012; 15: 843-50.
14. Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, et al. Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. *Respir Med* 2011.
15. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. *Value Health* 2004; 7: 153-67.
16. Hansen RN, Xu X, Sullivan SD. A dynamic cohort model of chronic obstructive pulmonary disease and its treatments. *Value Health* 2012; 15: A54.
17. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, Al MJ, Feenstra TL. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. *Value Health* 2011; 14: 1039-1047.
18. Rutten-van Molken MP, Oostenbrink JB, Miravittles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. *Eur J Health Econ* 2007; 8: 123-135.

19. Samyshkin Y, Kotchie RW, Mork AC, Briggs AH, Bateman ED. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. *Eur J Health Econ* 2013.
20. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. *Pharmacoeconomics* 2012; 30: 825-840.
21. Nielsen R, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, Gulsvik A, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. *Eur Respir J* 2009; 34: 850-857.
22. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. *Pharmacoeconomics* 2005; 23: 619-37.
23. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, eds. Global Initiative for Chronic Obstructive Lung Disease. Workshop Report: Global Strategy for the Diagnosis, Management and Prevention of COPD: Updated 2003. NHLBI/WHO, Bethesda, 2003.
24. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, et al. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. *Respir Med* 2003; 97: 115-22.
25. Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. *PLoS One* 2011; 6: e24870.
26. Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. *Value Health* 2011; 14: 354-360.
27. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, et al. A dynamic population model of disease progression in COPD. *Eur Respir J* 2005; 26: 223-33.

28. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. *Thorax* 2010; 65: 711-718.
29. Hoogendoorn M, Rutten-van Molken MPMH, Hoogenveen RT, Al MJ, Feenstra TL, eds. Working Paper: Comparing the Cost-Effectiveness of a Wide Range of COPD Interventions using a Stochastic, Dynamic, Population Model for COPD. Erasmus University Rotterdam, Institute of Health, Policy and Management, Rotterdam, The Netherlands, 2010.
30. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. *Value Health* 2005; 8: 32-46.
31. Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. *Int J Chron Obstruct Pulmon Dis* 2013; 8: 79-87.
32. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. *Int J Chron Obstruct Pulmon Dis* 2012; 7: 183-199.
33. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. *Value Health* 2012; 15: 835-842.
34. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. *Diabetes Care* 2007; 30: 1638-1646.
35. Palmer AJ, Mount Hood 5 Modeling Group. Computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. *Value Health* 2013; 16: 670-685.
36. Hornberger J. Computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. *Value Health* 2013; 16: 453-454.

37. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007; 356: 775-89.
38. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2008; 359: 1543-1554.
39. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. *Am J Respir Crit Care Med* 2012; 186: 975-981.
40. Soriano JB, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ, et al. Distribution and prognostic validity of the new global initiative for chronic obstructive lung disease grading classification. *Chest* 2013; 143: 694-702.
41. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, et al. Characteristics, stability and outcomes of the gold 2011 copd groups in the eclipse cohort. *Eur Respir J* 2013.
42. Asukai Y, Baldwin M, Fonseca T, Gray A, Mungapen L, Price D. Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach. *Pharmacoeconomics* 2013; 31: 151-161.
43. Briggs A, Lomas D, Rutten-van Molken M, Taberer M, Chambers M, Muellerova H, et al. Developing a new model of COPD: from conceptualisation to implementation to validation. *Value Health* 2013; 16: A234-A235.

Table 1: Overview disease progression

| | Framework | Subgroup specifications | Transition probability in the first year for a 65-year old ex-smoking male patient with moderate COPD |
|-------------------|--|---|--|
| Asukai | Annual decline in lung function of 30ml/yr obtained from the UPLIFT trial used to calculate transition probabilities | No subgroup specification in annual decline | Moderate to severe: 4.3% Moderate to very severe: 0.1% |
| Borg | Transition probabilities based on the 10-year follow-up data of the OLIN studies. 1. Base risk 2. Risk related to exacerbations | Transition rates specified by COPD disease severity and age | Moderate to mild: 5.0% Moderate to severe: 6.0% Moderate to very severe: 0% |
| Hansen | Transition probabilities adapted from Atsou et al.: mild/moderate COPD based on the BOLD cohort, for severe to very severe adapted from Hoogendoorn et al (Lung Health Study) | Transition rates specified by age, smoking status and COPD disease severity | Moderate to severe: 8.3% Moderate to very severe: 0.3% |
| Hoogendoorn | Annual decline in lung function obtained from a re-analysis of the original 5-year data of the Lung Health Study | Annual decline specified by sex, age, smoking status and COPD severity | Moderate to severe: 3.2% Moderate to very severe: 0% |
| Rutten-van Mülken | First year: annual decline in lung function as observed in six tiotropium trials. Year 2-5: Annual decline in lung function of 52 ml/yr obtained from the Lung Health Study applied to the patient population in two trials to calculate the transition probabilities | No subgroup specification in annual decline. | Moderate to severe: 32% Moderate to very severe: 6.6% |
| Samyshkin | Annual decline in lung function of 52ml/yr obtained from the Lung health Study used to calculate time to transition and transition probabilities | No subgroup specification in annual decline | Moderate to severe: 7.0% Moderate to very severe: 0.4% |
| Wacker | Annual decline in lung function for mild/moderate COPD based on the Lung Health Study (smokers: 60ml/yr, former smokers: 27 ml/yr), for smokers with severe COPD based on the ISOLDE+TORCH trial. | Annual decline specified by smoking | Moderate to severe: 1.1% Moderate to very severe: 0.01% |

| | | | |
|--|--|--|--|
| | Decline was transformed into time to transition and transition probabilities | | |
|--|--|--|--|

Table 2: Overview mortality after standardization for background mortality

| | Framework | Subgroup specifications | Probability to die in the first year for a 65-year old ex-smoking male patient with moderate COPD |
|-------------------|---|--|--|
| Asukai | Total mortality: 1. All-cause mortality obtained from death tables (not adjusted for COPD-specific deaths) 2. COPD-related mortality | 1. Specified by sex and age 2. Specified by COPD disease severity | Total mortality: 2.7% 1. 1.5% 2. 1.2% |
| Borg | Total mortality: 1. Base mortality 2. Mortality related to severe exacerbations | 1. Specified by age, and disease severity 2. Specified by age, and disease severity | Total mortality: 4.6% (with average number of severe exacerbations) |
| Hansen | Total mortality: 1. All-cause mortality from life tables 2. Exacerbation-related mortality: relative risks applied to all-cause mortality in the general population associated with moderate and severe exacerbations by COPD stage | 1. All-cause mortality by sex and age 2. Exacerbation-related mortality by COPD disease severity and severity of the exacerbation | Total mortality: 3.6% 1. 1.5% without exacerbation 2. 2.4% with a moderate exacerbation 3. 3.15% with a severe exacerbation |
| Hoogendoorn | Total mortality: 1. Mortality due to other causes including other smoking-related diseases 2. COPD attributable mortality excluding mortality due to exacerbations 3. Exacerbation-related mortality | 1. Specified by sex, age and smoking status 2. Specified by sex, age and COPD disease severity 3. Specified by age | Total mortality: 6.0% 1. 1.5% 2. 2.2% 3. 2.3% |
| Rutten-van Mólken | Total mortality | Specified by COPD disease severity | Total mortality: 6.6% |
| Samyshkin | Total mortality: 1. Non-COPD related mortality 2. Increased COPD-related mortality including a 7.7% case fatality associated with a severe exacerbation | 1. Specified by sex and age 2. Specified by COPD disease severity | Total mortality: 2.9% 1. 1.5% 2. 1.4% |
| Wacker | Total mortality: 1. Mortality in stable disease | | Total mortality: 7.4% 1. 3.5% |

| | | | |
|--|--|---|---|
| | <ul style="list-style-type: none"> - Background mortality - COPD-related mortality <p>2. Mortality associated with severe exacerbations (surgery and transplantation <60yr)</p> | <p>1. Specified by age, COPD disease severity and smoking</p> <p>2. Specified by age (and disease stage, smoking status for AE-mortality)</p> | <ul style="list-style-type: none"> - 1.5% - 2.0% <p>2. 3.9%</p> |
|--|--|---|---|

Table 3: Input variables to standardize the reference scenario

| Variable | Value* |
|--|--|
| Sex | Male |
| Age | 65 years |
| Smoking status | Ex-smoking |
| COPD disease severity # | Moderate COPD (GOLD guidelines) or a mean FEV1 of 65% predicted |
| Baseline total exacerbation frequency by COPD severity# | 0.82 (0.26), 1.17 (0.15), 1.61 (0.06), 2.10 (0.36) |
| Baseline severe exacerbation frequency by COPD severity# | 0.11 (0.14), 0.16 (0.07), 0.22 (0.01), 0.28 (0.13) |
| Mortality due to other causes than COPD | 1.5% (0.23) |
| Utilities during stable disease by COPD severity# | 0.90 (0.11), 0.787 (0.008), 0.750 (0.0093), 0.647 (0.0241) |
| Annual costs for treating stable disease by COPD severity# | €100 (15), €300 (45), €650 (98), €1200 (180) |
| Reduction in baseline utility due to a moderate exacerbation | 1-month cycle: 18% (2.7), 3-month cycle: 6% (0.9), 1-year cycle: 1.5% (0.22) |
| Reduction in baseline utility due to severe exacerbation | 1-month cycle: 60% (9), 3-month cycle: 20% (3), 1-year cycle: 5% (0.75) |
| Costs for a moderate and severe exacerbation, respectively | €100 (15), €4000 (600) |

* Data are mean (se)

Four COPD severity stages based on the GOLD guidelines: mild ($FEV1 \geq 80\%$ of predicted), moderate ($50\% \leq FEV1 < 80\%$), severe ($30\% \leq FEV1 < 50\%$) and very severe COPD ($FEV1 < 30\%$).


Table 4: Five-year cost-effectiveness results for the four hypothetical interventions compared to no intervention

| | Asukai | Borg | Hansen | Hoogendoorn | Rutten | Samyshkin | Wacker |
|---|---------------|-------------|---------------|--------------------|---------------|------------------|---------------|
| Intervention 1: 20% reduction in disease progression | | | | | | | |
| - Difference in QALYs | 0.012 | 0.00020 | 0.0077 | 0.0035 | 0.039 | 0.018 | 0.0020 |
| - Difference in costs | €842 | €880 | €912 | €816 | €561 | €734 | €695 |
| - Cost-effectiveness ratio | €69,000 | €4,400,500 | €118,300 | €234,500 | €14,400 | €40,200 | €347,500 |
| | | | | | | | |
| Intervention 2: 25% reduction in exacerbations | | | | | | | |
| - Difference in QALYs | 0.018 | 0.024 | 0.0089 | 0.056 | 0.020 | 0.046 | 0.075 |
| - Difference in costs | €1,249 | €1,350 | €942 | €961 | €739 | €926 | €844 |
| - Cost-effectiveness ratio | €68,900 | €56,000 | €106,300 | €17,300 | €37,000 | €20,200 | €11,300 |
| | | | | | | | |
| Intervention 3: 10% reduction in mortality | | | | | | | |
| - Difference in QALYs | 0.026 | 0.017 | 0.045 | 0.034 | 0.048 | 0.025 | 0.047 |
| - Difference in costs | €1,431 | €1,465 | €1,618 | €1,345 | €315 | €1,361 | €1,140 |
| - Cost-effectiveness ratio | €55,500 | €87,200 | €35,700 | €39,300 | €27,400 | €55,400 | €24,300 |
| | | | | | | | |
| Intervention 4: combination of effects intervention 1 to 3 | | | | | | | |
| - Difference in QALYs | 0.056 | 0.10 | 0.054 | 0.091 | 0.11 | 0.086 | 0.12 |
| - Difference in costs | €2,608 | €2,903 | €2,570 | €2,295 | €854 | €2,173 | €2,002 |
| - Cost-effectiveness ratio | €46,700 | €27,800 | €47,400 | €25,300 | €17,400 | €25,300 | €16,800 |

Table 5: Lifetime cost-effectiveness results for the four hypothetical interventions compared to no intervention

| | Asukai | Borg | Hansen | Hoogendoorn | Samyshkin | Wacker |
|---|---------------|-------------|---------------|--------------------|------------------|---------------|
| Intervention 1: 20% reduction in disease progression | | | | | | |
| - Difference in QALYs | 0.357 | 0.110 | 0.083 | 0.081 | 0.270 | 0.030 |
| - Difference in costs | €1,893 | €4,051 | €1,735 | €1,633 | €5,591 | €1,427 |
| - Cost-effectiveness ratio | €5,300 | €36,700 | €21,000 | €0,100 | €5,900 | €47,600 |
| | | | | | | |
| Intervention 2: 25% reduction in exacerbations | | | | | | |
| - Difference in QALYs | 0.060 | 0.317 | 0.087 | 0.366 | 0.205 | 0.382 |
| - Difference in costs | €2,953 | €7,917 | €1,629 | €2,419 | €1,113 | €2,143 |
| - Cost-effectiveness ratio | €49,500 | €25,000 | €18,600 | €6,600 | €10,300 | €5,600 |
| | | | | | | |
| Intervention 3: 10% reduction in mortality | | | | | | |
| - Difference in QALYs | 0.581 | 0.255 | 0.616 | 0.347 | 0.259 | 0.336 |
| - Difference in costs | €4,211 | €7,012 | €5,175 | €3,463 | €5,568 | €2,762 |
| - Cost-effectiveness ratio | €7,300 | €27,500 | €8,400 | €0,000 | €13,800 | €8,200 |
| | | | | | | |
| Intervention 4: combination of effects intervention 1 to 3 | | | | | | |
| - Difference in QALYs | 1.030 | 0.533 | 0.714 | 0.806 | 0.751 | 0.755 |
| - Difference in costs | €6,938 | €14,579 | €6,886 | €6,018 | €5,595 | €5,146 |
| - Cost-effectiveness ratio | €6,700 | €27,300 | €10,000 | €7,500 | €7,400 | €6,800 |

A)



B)





Figure 1: Comparison of five-year model outcomes for the reference scenario, discount rate both costs and effects 3%, a) severity distribution and mortality, b) mean number of exacerbations and (quality-adjusted) life years per patient

* Total exacerbations was not an outcome in the model of Hansen

A)



B)




Figure 2: Uncertainty around the results of intervention four for a five-year time horizon: mean and 95% confidence intervals around A) difference in QALYs, B) difference in costs




Figure 3: Acceptability curve for intervention four, five year time horizon

Appendix I: Overview of the different parameters for which uncertainty is included in the models (before standardization)

| | Asukai | Borg | Hansen | Hoogendoorn | Rutten-van Mólken | Samyshkin | Wacker |
|--|---------------|-------------|---------------|--|--------------------------|------------------|---------------|
| Starting FEV ₁ | Yes | No | Yes | Yes | No | No | No |
| Disease progression | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Exacerbation probabilities | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Mortality probabilities | Yes | Yes | No | Yes | Yes | Yes | Yes |
| Utilities for stable disease | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Utility reduction due to an exacerbation | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Costs for treating stable disease | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Costs for exacerbations | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Other parameters | - | - | - | Prevalence, incidence and exacerbation-related annual decline FEV ₁ | - | - | - |